Assay Guidance Workshop for High Throughput Screening and Lead Discovery

Sunday, February 4, 2024

8:15 AM – 5:00 PM EST

Room/Location: 102A

MP

Mackenzie Pearson, PhD (she/her/hers)

Eli Lilly, Indiana, United States
Thomas D.Y Chung, PhD (he/him/his)

Sanford Burnham Prebys Medical Discovery Institute, California, United States
Nathan P. Coussens, PhD

Frederick National Laboratory for Cancer Research, Maryland, United States
Timothy L. Foley, PhD

Pfizer, CT, United States
Sarine Markossian, PhD (she/her/hers)

NCATS/NIH, Maryland, United States
Terry Riss, PhD (he/him/his)

Promega Corporation, Wisconsin, United States
Joe Trask, n/a

Revvity, Massachusetts, United States
AG

Abigail Grossman

NCATS, Maryland, United States

Handout
Douglas S. Auld, PhD (he/him/his)

Novartis-CBT-HTB-2, Massachusetts, United States
Philip Iversen, PhD (he/him/his)

Luther College, Iowa, United States

This full-day workshop will cover a broad range of critical concepts underlying assay development and implementation for high-throughput screening (HTS) and lead discovery projects. This workshop is designed to disseminate critical information about the implementation of robust assay methods and is particularly relevant for researchers developing molecular probes or clinical candidates. Many of the instructors have 20 to 30 years of experience in the field of drug discovery and will share information not readily found in a classroom or published material outside of the AGM.